We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come?
- Authors
Stahl, andreas; Hellstrom, ann; Smith, Lois E.H.
- Abstract
Treatment of retinopathy of prematurity (ROP) is currently evolving. Novel therapeutic options are emerging that have the potential to complement existing therapies and improve treatment outcomes. However, any new therapeutic option must be thoroughly evaluated before existing (and successful) treatment paradigms can be amended. This is particularly so when switching from locally effective therapies like photoablative laser therapy to systemic pharmacological treatments, which may have hitherto unknown widespread side effects. This review compiles the current knowledge of where and when the two most advanced pharmacological treatment options for ROP, insulin-like growth factor-1 supplementation and anti-vascular endothelial growth factor treatment, may have their place in future therapy regimens for ROP. The requirement for clinical studies is emphasized: these are needed to address safety considerations before any of these interventions can achieve the status of standard clinical care in the very vulnerable population of ROP infants. © 2014 S. Karger AG, Basel
- Subjects
SOMATOMEDIN C; VASCULAR endothelial growth factors; RETROLENTAL fibroplasia; PHOTODYNAMIC therapy; S. Karger AG
- Publication
Neonatology (16617800), 2014, Vol 106, Issue 3, p254
- ISSN
1661-7800
- Publication type
Article
- DOI
10.1159/000365132